These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://monicandek350043.blogginaway.com/39851750/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide